| Sign In to gain access to subscriptions and/or personal tools. |
Pelizaeus-Merzbacher Disease and Spastic Paraplegia Type 2Two Faces of Myelin Loss From Mutations in the Same GeneNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, hudsonl{at}ninds.nih.gov Pelizaeus-Merzbacher disease and X-linked spastic paraplegia type 2 are two sides of the same coin. Both arise from mutations in the gene encoding myelin proteolipid protein. The disease spectrum for Pelizaeus-Merzbacher disease and spastic paraplegia type 2 is extraordinarily broad, ranging from a spastic gait in the pure form of spastic paraplegia type 2 to a severely disabling form of Pelizaeus-Merzbacher disease featuring hypotonia, respiratory distress, stridor, nystagmus, and profound myelin loss. The diverse disease spectrum is mirrored by the underlying pathogenesis, in which a blockade at any stage of myelin proteolipid protein synthesis and assembly into myelin spawns a unique phenotype. The continuing definition of pathogenetic mechanisms operative in Pelizaeus-Merzbacher disease and spastic paraplegia type 2, together with advances in neural cell transplant therapy, augurs well for future treatment of the severe forms of Pelizaeus-Merzbacher disease. (J Child Neurol 2003;18:616—624).
Journal of Child Neurology, Vol. 18, No. 9,
616-624 (2003) This article has been cited by other articles:
|
|
||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
